Aumolertinib Combined with Carbamazepine and Intrathecal Pemetrexed for EGFR-mutated LM NSCLC with Symptomatic Epilepsy

被引：0
|
作者：
Li, L. [1 ]
Yang, M. [2 ]
Huang, D. Y. [1 ]
Liu, F. [2 ]
Zhang, L. [3 ]
Song, X. W. [1 ]
Lv, Y. J. [1 ]
Teng, C. [1 ]
Fan, C. J. [1 ]
Tian, D. [1 ]
Shen, W. X. [1 ]
Jiang, Q. Y. [1 ]
Lu, D. [1 ]
Xin, T. [1 ]
机构：
[1] Harbin Med Univ, Affiliated Hosp 2, Harbin, Peoples R China
[2] China Japan Friendship Hosp, Beijing, Peoples R China
[3] Daqing Oilfield Gen Hosp, Daqing, Heilongjiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Aumolertinib; Intrathecal; injection; Symptomatic epilepsy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-42
引用
收藏
页码：S351 / S351
页数：1
相关论文
共 50 条
  • [1] Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles
    Wang, W.
    Fan, S. B.
    Huang, X. P.
    Zhong, M. X.
    Guo, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S338 - S338
  • [2] High-Dose Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC with Meningeal Symptoms as the First Symptom
    Wang, W.
    Fan, S. B.
    Huang, X. P.
    Zhong, M. X.
    Guo, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S650 - S650
  • [3] High-Dose Aumolertinib Combined Intrathecal Chemotherapy for the Treatment of EGFR-Mutated NSCLC with Leptomeningeal Metastasis
    Wang, W.
    Zhong, M.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S625 - S626
  • [4] A Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases
    Zhang, X.
    Zhang, M.
    Du, X.
    Zhang, G.
    Niu, Y.
    Wei, C.
    Guo, L.
    Shi, C.
    Wang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S660 - S660
  • [5] Case report: A case report and literature review on the efficacy of high-dose aumolertinib combined intrathecal pemetrexed by Ommaya reservoir for EGFR-mutated NSCLC with leptomeningeal metastasis as the initial symptoms
    Zhong, Maoxi
    Zhou, Li
    Guo, Jing
    Chen, Chuan
    Wang, Wei
    Huang, Xiaoping
    Liu, Yi
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [6] Efficacy and safety of high dose furmonertinib combined with intrathecal injection in EGFR-mutated advanced NSCLC patients with LM progressed on osimertinib
    Li, X.
    Zheng, X.
    An, J.
    Hua, Y.
    Ding, X.
    Shi, H.
    Xu, W.
    Li, Y.
    Zhou, L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [7] A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis
    Fang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S422 - S422
  • [8] An Effective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using Aumolertinib
    Zhang, X.
    Wu, Y.
    Hu, Y.
    Zhang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S415 - S415
  • [9] EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
    Gu, Weiguang
    Zhang, Hua
    Lu, Yiyu
    Li, Minjing
    Yang, Shuang
    Liang, Jianmiao
    Ye, Zhijian
    Li, Zhihua
    He, Minhong
    Shi, Xiaoliang
    Wang, Fei
    You, Dong
    Gu, Weiquan
    Feng, Weineng
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 841 - 850
  • [10] Long Survival in LM NSCLC Treated with Aumolertinib and Metronomic Intrathecal Pemetrexed under Dynamic Detection of CSF ctDNA
    Dai, Z. X.
    Cui, S. Q.
    Li, D.
    Liu, X.
    Song, J. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S668 - S668
12345